



BioNTech Recognizes Employees and Partners for Their Support in Developing Historic Vaccine

December 31, 2020

MAINZ, Germany, December 31, 2020 —[BioNTech SE](#) (Nasdaq: BNTX) today wants to express its thanks and gratitude not only to its employees but also to the many partners who have assisted the company in successfully developing a vaccine for COVID-19. BioNTech acknowledges that without the tireless effort from its' employees and partners, who have played a pivotal role in this effort, it would not have been able to achieve this historic company milestone, a journey which only began in early 2020. Data from its Phase 3 study have demonstrated that the vaccine is well-tolerated and 95% effective in preventing COVID-19. The vaccine has already received conditional marketing authorizations as well as emergency use authorizations in more than 45 countries around the world, including the United States and the European Union.

BioNTech's employees have made a significant contribution to this initiative, working around the clock to harness the power of mRNA and apply it to this effort of fighting against the devastating pandemic. In addition, our partner companies and organizations have provided the company with research expertise, critical supply support, and valuable insights and assistance throughout the development and trial process. Without them, achieving this result only 11 months after the initiation of Project Lightspeed would not have been possible.

"To address a global challenge like COVID-19, we have undertaken a worldwide effort to develop a well-tolerated and effective vaccine as quickly as science and cutting-edge technology will allow," said **Ugur Sahin, M.D., CEO and Co-founder of BioNTech**. "Despite the damage caused by the virus, I have been inspired each day by the spirit of collaboration and scientific discovery. It is one of the greatest honors of my life to be involved in this effort and to play a role in helping the world regain a sense of normality. I would like to thank each and every person that helped make this a reality."

BioNTech's management and employees appreciate the relentlessly support of many companies. A full list of BioNTech's partners supporting the COVID-19 project can be found below and at this [link](#).

Our Partners:

A-C	D-L	M-P	Q-Z
A&C Biobuffer	D-HCC Dopamine Healthcare Communication	MACHEREY-NAGEL	QIAGEN
Acuitas	Dätwyler Holding	Marble Pharma Consult	Ragon Institute of MGH, MIT and Harvard
Admedicum	Delpharm	Medidata	Ramsay Pharma
Agilent Technologies Sales & Services	Dermapharm	medwiss-extern	RD-Biotech
Alexis Carpenter Consulting	DHL	Merck	Real Life Sciences
ALFA Chemicals	Discovery Life Sciences	Merck Chemicals	Regeneron
Almac Clinical Services	Dr. Liebscher Consulting	Meso Scale Diagnostics	Rentschler
Applied Critical Fluids	Dunn Labortechnik	Miltenyi Biotec	Sartorius Lab Instruments
Aristo Group	Entourage Pharma Consulting	mpütranslations	Sartorius Stedim Biotech
auceris	Eppendorf Vertrieb Deutschland	Mundicare	Schott
Avanti Polar Lipids	Eurobio Scientific	nerbe plus	Siegfried
Avia Pharma	Eurofins Genomics Germany	New England Biolabs	Sigma-Aldrich Chemie
Baxter	Evonik Industries	National Institutes of Health (NIH)	Sino Biological Europe
Becton Dickinson	Finsbury Glover Hering Corporation	Novartis	Sinus Event-Technik
Bexon Clinical Consulting	Fisher Scientific	ONE LOGIC	Staburo
Biaffin	Fosun Pharma	ORIGIO Clinical Monitoring	Stephenson Harwood
BioCat	FreshFields Bruckhaus Deringer	Osborne ClarkeG	Stevenato Group
BioLegend Europe	Gowling WLG	Panhans Pharma Consul	SyroCon Consulting
Biomay	Granzer Regulatory Consulting & Service	Paul Hastings	Tecan Deutschland

Biotrend Chemikalien	Greiner Bio-One	Pfizer	Thermo Fisher Scientific
Biozol Diagnostica Vertrieb	GlaxoSmithKline (GSK)	PharmaCentaur	THERON Management Advisors
Brand Institute	Hözel Diagnostika Handels	PHARM-SOFT Dr. B. Rodu	Topmedicare
Carl Roth	Horváth & Partner	PHMR	TriLink BioTechnologies
Catalent	ICON	Phoenix-Apotheke Mainz	TriRadial Solutions
CG Pharma	Informa Pharma Intelligence	Pixilicious Enterprises	TRON
Chemengineering	Instadeep	Plan@ IT Services	Trophic Communications
Choate Hall & Stewart	K-Recruiting	Polymun	Universitätsklinikum Frankfurt
CMS Legal Services	Kerafast	portvier	UniversitätsKlinikum Heidelberg
Cognigy	Kissel Pharma Consulting	Powell Gilbert	VisMederi
Cole-Parmer	LGC Genomics	Precision Bioservices	VWR International
Consulimus	Life Technologies (Thermo Fisher Scientific)	Precision for Medicin	WE Communications
Corning	LKF-Laboratorium für Klinische Forschung	Profishop-Bremee	World Courier
Covington		ProfiLab24	ZSP Patentanwälte
CRB Group		Progressive Recruitment	
Croda International		pure 11	
CRS Clinical Research Services Mannheim		PriceWaterhouseCoopers (PwC)	

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

BioNTech Contacts:

Media Relations

Jasmina Alatovic
+49 89 62 81 75 46
Media@biontech.de

Investor Relations

Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de